EGFR and non-small cell lung carcinoma: Among them, the Chinese Society of Clinical Oncology (CSCO) Guidelines for NSCLC (2025), the most authoritative NSCLC guideline in China, recommends EGFR-TKIs as the first-line therapy for patients with stage IV EGFR-mutant NSCLC (Huang et al., 2020).